Abstract
Cervical cancer is ranked the fourth most common cause of cancer related deaths amongst women. The situation is
particularly dire in low to lower middle-income countries. It continues to affect these countries due to poor vaccine coverage and
screening. Cervical cancer is mostly detected in the advanced stages leading to poor outcomes. This review focuses on the progress
made to date to improve early detection and targeted therapy using both circulating RNA. Vaccine has played a major role in cervical
cancer control in vaccinated young woman in mainly developed countries yet in low-income countries with challenges of 3 dose
vaccination affordability, cervical cancer continues to be the second most deadly amongst women. In this review, we show the progress
made in reducing cervical cancer using vaccination that in combination with other treatments that might improve survival in cervical
cancer. We further show with both miRNA and siRNA that targeted therapy and specific markers might be ideal for early detection of
cervical cancer in low-income countries. These markers are either upregulated or down regulated in cancer providing clue to the stage
of the cancer.